The current lack of effective treatments for Alzheimer’s disease (AD) and the rapidly increasing burden of the disease highlight the urgent need to find new treatments. Despite accumulating evidence of the beneficial effects of rasagiline in neurodegenerative diseases such as Parkinson’s disease, the effects of rasagiline on the brains of patients with AD have not been elucidated.
Purpose
To examine the effects of rasagiline on regional cerebral flow (rCBF) in patients with AD using single photon emission computed tomography (SPECT).
Material and Methods
Among 22 patients with AD, 11 patients received adjunctive rasagiline at 1 mg/day in conjunction with acetylcholinesterase inhibitors (AChEI); 11 patients were only treated with AChEI for about 1.6 years. All patients underwent brain technetium-99m hexamethylpropylene amine oxime SPECT scans and clinical assessments at baseline and follow-up visits. Annual percent changes in rCBF were compared between the groups in a voxel-wise manner.
Results
SPECT analysis revealed that the rasagiline-treated group showed more increased rCBF in the cingulate gyrus, inferior frontal gyrus, putamen, and thalamus compared to the comparison group (P < 0.005).
Conclusion
We demonstrated that adjunctive rasagiline treatment may have beneficial effects on brain perfusion in patients with AD, suggesting potential neuroprotective effects.
GauthierS.Pharmacotherapy of mild cognitive impairment. Dialogues Clin Neurosci2004;
6:391–395.
2.
KoontzJBaskysA.Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. Am J Alzheimers Dis Other Demen2005;
20:295–302.
3.
PetersenRCThomasRGGrundmanM, et al.
Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med2005;
352:2379–2388.
4.
YoudimMBGrossAFinbergJP.Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol2001;
132:500–506.
5.
WuYKazumuraKMaruyamaW, et al.
Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore: a novel anti-apoptotic function for neuroprotection. J Neural Transm (Vienna)2015;
122:1399–1407.
6.
StefanovaNPoeweWWenningGK.Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol2008;
210:421–427.
7.
BlandiniFArmenteroMTFancelluR, et al.
Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Exp Neurol2004;
187:455–459.
8.
OlanowCWRascolOHauserR, et al.
A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med2009;
361:1268–1278.
9.
DemetriadesAK.Functional neuroimaging in Alzheimer’s type dementia. J Neurol Sci2002;
203–204:247–251.
10.
American Psychiatric Association.Diagnostic and statistical manual of mental disorders (DSM-IV-TR).
Washington, DC:
American Psychiatric Association, 2000.
11.
McKhannGDrachmanDFolsteinM, et al.
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984;
34:939–944.
12.
PickutBADierckxRADobbeleirA, et al.
Validation of the cerebellum as a reference region for SPECT quantification in patients suffering from dementia of the Alzheimer type. Psychiatry Res1999;
90:103–112.
13.
SoonawalaDAminTEbmeierKP, et al.
Statistical parametric mapping of (99m)Tc-HMPAO-SPECT images for the diagnosis of Alzheimer’s disease: normalizing to cerebellar tracer uptake. Neuroimage2002;
17:1193–1202.
14.
BrettMAntonJValabregueR, et al.
Region of interest analysis using the MarsBar toolbox for SPM 99. Neuroimage2002;
16:S497.
15.
Tzourio-MazoyerNLandeauBPapathanassiouD, et al.
Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage2002;
15:273–289.
16.
KangYNaDLHahnS.A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients. J Korean Neurol Assoc1997;
15:300–308.
17.
MorrisJCHeymanAMohsRC, et al.
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology1989;
39:1159–1165.
18.
KogureDMatsudaHOhnishiT, et al.
Longitudinal evaluation of early Alzheimer’s disease using brain perfusion SPECT. J Nucl Med2000;
41:1155–1162.
19.
KillianyRJGomez-IslaTMossM, et al.
Use of structural magnetic resonance imaging to predict who will get Alzheimer’s disease. Ann Neurol2000;
47:430–439.
20.
LeechRSharpDJ.The role of the posterior cingulate cortex in cognition and disease. Brain2014;
137:12–32.
21.
JonesBFBarnesJUylingsHB, et al.
Differential regional atrophy of the cingulate gyrus in Alzheimer disease: a volumetric MRI study. Cereb Cortex2006;
16:1701–1708.
22.
ShelineYIRaichleMESnyderAZ, et al.
Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry2010;
67:584–587.
23.
LiWAntuonoPGXieC, et al.
Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer’s disease after 12-week donepezil treatment. Neuroimage2012;
60:1083–1091.
24.
CorbettaMShulmanGL.Control of goal-directed and stimulus-driven attention in the brain. Nat Rev Neurosci2002;
3:201–215.
25.
HampshireAOwenAM.Fractionating attentional control using event-related fMRI. Cereb Cortex2006;
16:1679–1689.
26.
DoddsCMMorein-ZamirSRobbinsTW.Dissociating inhibition, attention, and response control in the frontoparietal network using functional magnetic resonance imaging. Cereb Cortex2011;
21:1155–1165.
27.
WeinrebOMandelSBar-AmO, et al.
Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer’s disease drugs. Neurotherapeutics2009;
6:163–174.
28.
HeikkilaREDuvoisinRCFinbergJP, et al.
Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol1985;
116:313–317.
29.
SpeiserZMaykAEliashS, et al.
Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm (Vienna)1999;
106:593–606.
30.
YoudimMBAmitTFalach-YogevM, et al.
The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol2003;
66:1635–1641.
31.
MaruyamaWTakahashiTYoudimM, et al.
The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm (Vienna) 2002;
109:467–481.
32.
WeinrebOBar-AmOAmitT, et al.
Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J2004;
18:1471–1473.
33.
OrreniusSZhivotovskyBNicoteraP.Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol2003;
4:552–565.
34.
GiorgiCBaldassariFBononiA, et al.
Mitochondrial Ca(2+) and apoptosis. Cell Calcium2012;
52:36–43.
35.
BorghammerPCummingPAanerudJ, et al.
Artefactual subcortical hyperperfusion in PET studies normalized to global mean: lessons from Parkinson’s disease. Neuroimage2009;
45:249–257.
36.
NeirinckxRDBurkeJFHarrisonRC, et al.
The retention mechanism of technetium-99m-HM-PAO: intracellular reaction with glutathione. J Cereb Blood Flow Metab1988;
8:S4–12.
